Cemat A/S
25.3.2021 08:20:59 CET | Globenewswire | Press release
Nasdaq Copenhagen
Nikolaj Plads 6
DK-1067 Copenhagen K
Copenhagen, 24 March 2021
ANNOUNCEMENT no 9/2021
Managers’ transactions
Pursuant to Article 19 of the market abuse regulation Cemat A/S hereby announces the following information received 23 March 2021.
| Name: | Joanna Lucyna Iwanowska-Nielsen |
| Reason for filing: | Insider |
| Company name: | Cemat A/S |
| Identification code and name: | ISIN DK0010271584 |
| Transaction type: | Purchase |
| Date: | 19 March 2021 |
| Market: | Nasdaq Copenhagen |
| Number of traded shares: | 75,000 |
| Price: | 0.50 |
Cemat A/S
Jaroslaw Pawel Lipinski
CEO
This announcement has been prepared in a Danish-language and an English-language
version. In case of doubt, the Danish version prevails.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Newcap Holdings29.3.2026 12:19:20 CEST | Pressemeddelelse
NewCap Holding A/S har indgået en aftale, betinget af underskrivelse af endelige aftaledokumenter m.v., om erhvervelse af dansk selskab indenfor compliance og risikostyringsservices – Intern viden
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom